Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sonia Messina

Showing results (81-90 of 162) with videos related to

Pageof 17
Sort By:
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|March 28, 2025
Patients on treatment with risdiplam in Italy: challenges in the interpretation of the real-world dataEmilio Albamonte, Adrea Lizio, Giorgia Coratti, et al.
Neuromuscular Disorders : NMD|October 21, 2019
Longitudinal natural history in young boys with Duchenne muscular dystrophyGiorgia Coratti, Claudia Brogna, Giulia Norcia, et al.
Plos One|August 1, 2019
Correction: Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53Claudia Brogna, Giorgia Coratt, Marika Pane, et al.
Plos One|June 26, 2019
Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53Claudia Brogna, Giorgia Coratti, Marika Pane, et al.
BMJ Open|August 13, 2017
Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial)Eleonora Dalla Bella, Irene Tramacere, Giovanni Antonini, et al.
Annals of Clinical and Translational Neurology|February 6, 2021
Type I SMA "new natural history": long-term data in nusinersen-treated patientsMarika Pane, Giorgia Coratti, Valeria A Sansone, et al.
Annals of Clinical and Translational Neurology|February 15, 2022
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophyMarika Pane, Giorgia Coratti, Maria Carmela Pera, et al.
Muscle & Nerve|June 27, 2015
Old measures and new scores in spinal muscular atrophy patientsElena Mazzone, Jacqueline Montes, Marion Main, et al.
Neuromuscular Disorders : NMD|February 27, 2016
Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort studySonia Messina, Gian Luca Vita, Maria Sframeli, et al.
Journal of Neurology|October 26, 2016
Factors predicting survival in ALS: a multicenter Italian studyAndrea Calvo, Cristina Moglia, Christian Lunetta, et al.
Pageof 17

Showing results (81-90 of 162) with videos related to

Sort By:
Pageof 17
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|March 28, 2025
Patients on treatment with risdiplam in Italy: challenges in the interpretation of the real-world dataEmilio Albamonte, Adrea Lizio, Giorgia Coratti, et al.
Neuromuscular Disorders : NMD|October 21, 2019
Longitudinal natural history in young boys with Duchenne muscular dystrophyGiorgia Coratti, Claudia Brogna, Giulia Norcia, et al.
Plos One|August 1, 2019
Correction: Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53Claudia Brogna, Giorgia Coratt, Marika Pane, et al.
Plos One|June 26, 2019
Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53Claudia Brogna, Giorgia Coratti, Marika Pane, et al.
BMJ Open|August 13, 2017
Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial)Eleonora Dalla Bella, Irene Tramacere, Giovanni Antonini, et al.
Annals of Clinical and Translational Neurology|February 6, 2021
Type I SMA "new natural history": long-term data in nusinersen-treated patientsMarika Pane, Giorgia Coratti, Valeria A Sansone, et al.
Annals of Clinical and Translational Neurology|February 15, 2022
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophyMarika Pane, Giorgia Coratti, Maria Carmela Pera, et al.
Muscle & Nerve|June 27, 2015
Old measures and new scores in spinal muscular atrophy patientsElena Mazzone, Jacqueline Montes, Marion Main, et al.
Neuromuscular Disorders : NMD|February 27, 2016
Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort studySonia Messina, Gian Luca Vita, Maria Sframeli, et al.
Journal of Neurology|October 26, 2016
Factors predicting survival in ALS: a multicenter Italian studyAndrea Calvo, Cristina Moglia, Christian Lunetta, et al.
Pageof 17